AbbVie Partnering Day

11:02 till 11:02 o'clock
Kalendereintrag speichern
Don’t miss this opportunity to meet with executives, team leaders and scientists from AbbVie pharmaceuticals to explore partnering opportunities.


AbbVie, a research-based global biopharmaceutical company, is working to solve some of the world’s toughest health challenges. AbbVie is seeking alliances, collaborations and strategic partners to complement its R&D programs. AbbVie’s interest areas are outlined below.

If you are a Discovery through phase I company with novel technologies complementing AbbVie’s interests and would like the opportunity to meet with the AbbVie team, please complete the application below no later than COB September 8, 2020.


AbbVie Therapeutic Areas of Interest


Stage: Discovery through Phase I
Areas of Interest:

  • Solid tumors and hematologic malignancies
  • Targeted therapies for regulated cell death, B-cell signaling, immuno-oncology
  • Next generations of targeted small molecules
  • Novel targeted biologics
  • New T-cell-engaging- and T-cell receptor-based approaches

Modalities: Small molecule, novel biologics, bispecific, fusion proteins, degraders, drug conjugates, next generation cell therapies.

Learn more about AbbVie’s Oncology focus here.


Stage: Discovery through Phase I
Areas of interest:

  • Crohn’s disease, ulcerative colitis
  • Psoriasis, atopic dermatitis
  • Rheumatology (RA, PsA, SpA)
  • Novel therapies for SLE, systemic sclerosis, Sjogrens syndrome
  • Fibrotic conditions associated with certain inflammatory conditions

Modalities: All

Learn more about AbbVie’s Immunology focus here.


Stage: Discovery through Phase I
Areas of interest:

  • Alzheimer’s disease
  • Parkinson’s disease
  • Other neurodegenerative diseases that share proteinopathy mechanisms with AD and PD
  • Multiple sclerosis
  • Psychiatry (major depressive disorder, bipolar depression, etc.)
  • Psychosis (negative and cognitive deficits, etc.)
  • Anxiety disorders
  • Migraine

Modalities: Disease related biomarkers and technologies, include: (i) disease-specific, diagnostic, prognostic and progression biomarkers (ii) Imaging tools, ligands and related techniques that allow estimation of target engagement in the brain, and (iii) wearable technologies that can enable better assessment of parameters in clinical trials.

Learn more about AbbVie’s Neuroscience focus here.


Stage: Discovery through Phase I

Areas of interest:

  • Age-related macular degeneration
  • Glaucoma
  • Dry eye/ocular surface diseases
  • Refractive conditions such as presbyopia and myopia

Modalities: Small molecules, biologics, drug delivery modalities, and technology platforms.


Stage: Preclinical through Phase I

Areas of interest:

  • HIV Functional Cure
  • COVID-19

Modalities: All

Learn more about AbbVie’s Virology focus here.

Women’s Health

Stage: Late Preclinical through Phase I

Areas of interest:

  • Vasomotor symptoms (VMS) in post-menopausal women and breast cancer patients
  • Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome (PCOS)
  • Contraception

Modalities: All

Learn more about AbbVie’s Women’s Health focus  here.


AbbVie Partnering Program Details

October 20, 2020 | 8:30am – 3:30 PDT | Live, Online

More details coming soon!

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on TwitterFacebookInstagramYouTube and LinkedIn.

The California Life Sciences Institute (CLSI)

CLSI is a non-profit that supports the foundations of innovation that have made California home to the world’s most prominent life sciences ecosystem.  The San Francisco Bay Area is a mature and experienced life science cluster offering deep expertise in the development and implementation of innovation in therapeutics, diagnostics, research tools, medical devices and synthetic biology.

To carry out its mission, CLSI has built a network of over 400 experienced industry professionals,  comprised predominantly of CEO’s and other senior executives across multiple functional areas and industry segments. The majority of CLSI’s (volunteer) advisors are in the Bay Area, but the network extends across the US and the Atlantic to the UK and the EU, and across the Pacific to Asia.  A graphic overview of our network of advisors follows this text.  With this network, CLSI operates three major programs aimed at guiding life science product developers as they navigate the path from idea to commercialization, providing advisory support to life science academics and entrepreneurs, in California and globally.